|
|
Volumn 28, Issue 11, 2010, Pages
|
|
Comparative in vitro cellular data alone are insufficient to predict clinical responses and guide the choice of BCR-ABL inhibitor for treating imatinib-resistant chronic myeloid leukemia
|
|
Author keywords
[No Author keywords available]
|
|
Indexed keywords
BCR ABL PROTEIN;
BOSUTINIB;
DASATINIB;
IMATINIB;
NILOTINIB;
BCR ABL TYROSINE KINASE;
BCR-ABL TYROSINE KINASE;
PIPERAZINE DERIVATIVE;
PROTEIN KINASE INHIBITOR;
PROTEIN TYROSINE KINASE;
PYRIMIDINE DERIVATIVE;
ANTINEOPLASTIC ACTIVITY;
CANCER RESISTANCE;
CHRONIC MYELOID LEUKEMIA;
DRUG CHOICE;
DRUG EFFICACY;
DRUG POTENCY;
DRUG SENSITIVITY;
GENE MUTATION;
HUMAN;
IC 50;
IN VITRO STUDY;
IN VIVO STUDY;
LETTER;
LEUKEMIA CELL;
MAXIMUM PLASMA CONCENTRATION;
MUTANT;
PRIORITY JOURNAL;
TREATMENT RESPONSE;
WILD TYPE;
CELL SURVIVAL;
COMPARATIVE STUDY;
DRUG ANTAGONISM;
DRUG RESISTANCE;
GENETICS;
METABOLISM;
NOTE;
PATHOLOGY;
PRACTICE GUIDELINE;
CELL SURVIVAL;
DRUG RESISTANCE, NEOPLASM;
FUSION PROTEINS, BCR-ABL;
HUMANS;
LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE;
PIPERAZINES;
PRACTICE GUIDELINES AS TOPIC;
PROTEIN KINASE INHIBITORS;
PROTEIN-TYROSINE KINASES;
PYRIMIDINES;
|
|
EID: 77951648806
PISSN: 0732183X
EISSN: 15277755
Source Type: Journal
DOI: 10.1200/JCO.2009.26.4945 Document Type: Letter |
|
Times cited : (53)
|
|
References (6)
|
